RNA interference-based therapy and its delivery systems

被引:242
作者
Chen, Xiuhui [1 ,2 ]
Mangala, Lingegowda S. [1 ,3 ]
Rodriguez-Aguayo, Cristian [3 ,4 ]
Kong, Xianchao [2 ]
Lopez-Berestein, Gabriel [3 ,4 ]
Sood, Anil K. [1 ,3 ,5 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA
[2] Harbin Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Harbin, Heilongjiang, Peoples R China
[3] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
RNA interference; Delivery systems; Nanoparticles; Cancer therapy; MESENCHYMAL STEM-CELLS; NANOSTRUCTURED LIPID CARRIERS; POLYMER HYBRID NANOPARTICLES; VASCULAR ENDOTHELIAL-CELLS; BLOOD-BRAIN-BARRIER; HEPATITIS-B-VIRUS; SIRNA DELIVERY; TARGETED DELIVERY; MULTIDRUG-RESISTANCE; BREAST-CANCER;
D O I
10.1007/s10555-017-9717-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
RNA interference (RNAi) is considered a highly specific approach for gene silencing and holds tremendous potential for treatment of various pathologic conditions such as cardiovascular diseases, viral infections, and cancer. Although gene silencing approaches such as RNAi are widely used in preclinical models, the clinical application of RNAi is challenging primarily because of the difficulty in achieving successful systemic delivery. Effective delivery systems are essential to enable the full therapeutic potential of RNAi. An ideal nanocarrier not only addresses the challenges of delivering naked siRNA/miRNA, including its chemically unstable features, extracellular and intracellular barriers, and innate immune stimulation, but also offers "smart" targeted delivery. Over the past decade, great efforts have been undertaken to develop RNAi delivery systems that overcome these obstacles. This review presents an update on current progress in the therapeutic application of RNAi with a focus on cancer therapy and strategies for optimizing delivery systems, such as lipid-based nanoparticles.
引用
收藏
页码:107 / 124
页数:18
相关论文
共 198 条
[1]   Nonviral delivery of synthetic siRNAs in vivo [J].
Akhtar, Saghir ;
Benter, Ibrahim F. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (12) :3623-3632
[2]  
[Anonymous], 2015, BioMed Res Int
[3]   Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality [J].
Arkin, Michelle R. ;
Tang, Yinyan ;
Wells, James A. .
CHEMISTRY & BIOLOGY, 2014, 21 (09) :1102-1114
[4]   siRNA-Aptamer Chimeras on Nanoparticles: Preserving Targeting Functionality for Effective Gene Silencing [J].
Bagalkot, Vaishali ;
Gao, Xiaohu .
ACS NANO, 2011, 5 (10) :8131-8139
[5]   Clinical translation of RNAi-based treatments for respiratory diseases [J].
Ballarin-Gonzalez, Borja ;
Thomsen, Troels Bo ;
Howard, Kenneth Alan .
DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2013, 3 (01) :84-99
[6]  
Barik S, 2015, METHODS MOL BIOL, V1218, P251, DOI 10.1007/978-1-4939-1538-5_14
[7]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[8]   Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors [J].
Beg, Muhammad S. ;
Brenner, Andrew J. ;
Sachdev, Jasgit ;
Borad, Mitesh ;
Kang, Yoon-Koo ;
Stoudemire, Jay ;
Smith, Susan ;
Bader, Andreas G. ;
Kim, Sinil ;
Hong, David S. .
INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) :180-188
[9]   Chemical Modification of siRNAs for In Vivo Use [J].
Behlke, Mark A. .
OLIGONUCLEOTIDES, 2008, 18 (04) :305-319
[10]   Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology [J].
Binzel, Daniel W. ;
Shu, Yi ;
Li, Hui ;
Sun, Meiyan ;
Zhang, Qunshu ;
Shu, Dan ;
Guo, Bin ;
Guo, Peixuan .
MOLECULAR THERAPY, 2016, 24 (07) :1267-1277